Seminars in Nuclear Medicine
Volume 40, Issue 2 , Pages 122-135 , March 2010

Radioimmunotherapy of Lymphoma: Bexxar and Zevalin

  • Stanley J. Goldsmith, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Stanley J. Goldsmith, MD, Division of Nuclear Medicine, Weill Cornell Medical Center, New York-Presbyterian Hospital, 525 E 68th St, New York, NY 10065

References 

  1. Davis TA, Grillo-López AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment. J Clin Oncol. 2000;18:3135–3143
  2. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495–497
  3. O'Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med. 1995;36:1902–1909
  4. Leonard JP, Siegel JA, Goldsmith SJ. Comparative physical and pharmacologic characteristics of iodine-131 and yttrium-90: Implications for radioimmunotherapy for patients with non-Hodgkin's lymphoma. Cancer Invest. 2003;21:241–252
  5. Arico D, Grana CM, Vanazzi A, et al. The role of dosimetry in the high activity 90Y-ibritumomab tiuxetan regimens: Two cases of abnormal biodistribution. Cancer Biother Radiopharm. 2009;24:271–275
  6. Wahl RL. Tositumomab and 131I therapy in non-Hodgkin's lymphoma. J Nucl Med. 2002;46:128S–140S
  7. Rutar FJ, Augustine SC, Colcher D, et al. Outpatient treatment with 131I-anti-B1 antibody: Radiation exposure to family members. J Nucl Med. 2001;42:907–915
  8. Harwood SJ, Rutar F, Sullivan G, et al. Bexxar radioimmunotherapy can be safely administered by healthcare professionals with minimal whole body exposure. J Nucl Med. 2003;44:327
  9. Wagner HN, Wiseman GA, Marcus CS, et al. Administration guidelines for radioimmunotherapy with 90Y-labeled anti-CD20 monoclonal antibody. J Nucl Med. 2002;43:267–272
  10. Britton K. Radioimmunotherapy of non-Hodgkin's lymphoma. J Nucl Med. 2004;45:924–925
  11. Fisher RI, Kaminski MS, Wahl RL, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol. 2005;23:7565–7573
  12. Leonard JP, Coleman M, Kostakoglu L, et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I-131 tositumomab for untreated follicular lymphoma. J Clin Oncol. 2005;23:5696–5704
  13. Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomabtherapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441–449
  14. Dosik AD, Coleman M, Kostakoglu L, et al. Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin's lymphoma. Cancer. 2006;106:616–622
  15. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncl. 2002;20:2453–2463
  16. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab refractory follicular non-Hodgkin's lymphoma. J Clin Oncl. 2002;20:3262–3269
  17. Morschauer F, Radford J, Van Hoff A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncl. 2008;26:5156–5164269
  18. Ansell SM, Schilder RJ, Pieslor PC, et al. Antilymphoma treatments given subsequent to yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: A review of the literature. Clin Lymphoma. 2004;5:202–204

PII: S0001-2998(09)00107-X

doi: 10.1053/j.semnuclmed.2009.11.002

Seminars in Nuclear Medicine
Volume 40, Issue 2 , Pages 122-135 , March 2010

Article Tools

* Image Usage & Resolution